Tetrapyrroles and derivatives
Abcam Pimobendan (Vetmedin), Ca2+ channel sensitizer, 10MG
MW 334.4 Da, Purity >99%. Ca2+ channel sensitizer. Selective PDE3 inhibitor. Inhibits platelet aggregation. Shows antithrombotic, antihypertensive, potent inotropic and vasodilatory effects *in vivo.* Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ibotenic acid, e x citoto x ic agonist, 1MG
MW 158.11 Da, Purity >98%. Neuroexcitatory amino acid originally isolated from Amanita species. Neurotoxin often used to model cognitive dysfunctions. NMDA and metabotropic receptor agonist.
The product is subject to the following: Abcam Restricted Use Statement
Frontier Specialty Chemicals 1G MESO-TETRA(4-CARBOXYPHENYL)
This item has a minimum qty of 2 per supplier requirements.
meso-Tetra(4-carboxyphenyl)porphine; CAS: 14609-54-2; 1g
Abcam Zaprinast, cGMP phosphodiesterase inhibitor, 10MG
MW 271.28 g/mol, Purity >98%. Specific cGMP phosphodiesterase inhibitor, selective for PDE6, 5, 11 and 9 (IC₅₀ values are 0.15 (PDE6), 0.76 (PDE5), 12 (PDE11) and 29 μM (PDE9)). Reputed GPR35 agonist (EC₅₀ values are 16 and 840 nM at rat and human GPR35 receptors, respectively). Important mediator for a variety of cellular processes including vasodilation.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GR 127935 hydrochloride, 5-HT1B/1D receptor antagonist, 10MG
MW 534.06 g/mol, Purity >97%. Potent and selective 5-HT₁B/₁D receptor antagonist (pKi = 8.5 for both 5-HT₁D in rat and 5-HT₁D in guinea pig). 100-fold selectivity over 5-HT₁A, 5-HT₁E, and 5-HT₂C. Displays centrally mediated effects upon systemic administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GBR 12909 dihydrochloride, Dopamine transport inhibitor, 10MG
MW 523.5 Da, Purity >98%. Potent, selective dopamine reuptake inhibitor (IC₅₀ = 2.32 μM in rat hippocampal slices; IC₅₀ = 6-35 μM in whole cell patch clamp recordings).
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY 294002, PI3-kinase inhibitor, 1MG
MW 307.3 Da, Purity >99%. A highly selective inhibitor of phosphatidylinositol 3-kinase (IC₅₀ = 1.4 μM). Selective over a range of other kinases including protein kinase C, protein kinase A, MAPK and PI4- kinase (IC₅₀ > 50 μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam UDP-glucose, Highly P2Y14 agonist, 1G
MW 610.27 Da. Highly potent, endogenous P2Y14 agonist (EC50 = 82 nM). Involved in modulation of gastric function. UDP also available (ab120383).
The product is subject to the following: Abcam Restricted Use Statement
Abcam (±)-Miconazole nitrate, Imidazole antifungal agent, 1G
MW 479.1 Da, Purity >99%. Imidazole antifungal agent. Inhibits fungal membrane ergosterol biosynthesis. Increases reactive oxygen species production.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BIM 23052, Somatostatin (sst5) receptor 5 agonist, 1MG
MW 1122.33 g/mol. Selective somatostatin (sst₅) receptor 5 agonist (Ki values are 7.3 (sst₅), 13.5 (sst₂), 31.3 (sst₁) and 141 nM (sst₄)). Role in gastrointestinal and neuroendocrine systems. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam x E-991 dihydrochloride, KCNQ channel blocker; blocks M current, 50MG
MW 449.4 Da, Purity >99%. Potent and selective blocker of KCNQ voltage-gated potassium channels. Blocks M current. (IC₅₀ values are 0.98 μM (M-current), 0.71 μM (KCNQ 2), 0.75 μM (KCNQX 1), >100 μM (Kv1.2) and >43 μM (Kv4.3). Potent pulmonary vasoconstrictor. Cognitive enhancer following oral administration in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WAY-100635 maleate, 5-HT1A receptor antagonist, 50MG
MW 538.6 Da, Purity >98%. Potent, selective, silent 5-HT1A receptor antagonist (IC50 = 1.35 nM). Displays >100-fold selectivity for 5-HT1Arelative to a range of other CNS receptors including other 5-HT subtypes, adrenoceptors, dopamine, GABA, histamine and ion channels. Binds selectively to rodent brain 5-HT1A receptors *in vivo* (iv admin). Unlike WAY100135, WAY100635 displays no partial agonist activity in the ventral hippocampus of rats.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (1-40) (human), 1MG
MW 4330 Da. beta-Amyloid Peptide (1-40) (human). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (42-1) (human), Inactive control, 1MG
MW 4514 Da. beta-Amyloid Peptide (42-1) (human), Inactive control. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 769662, AMP-activated protein kinase activator, 10MG
MW 360.4 Da, Purity >99%. Potent, reversible activator of AMP-activated protein kinase (AMPK) (EC₅₀ = 0.8 μM). Directly activates native rat AMPK by mimicking the effects of AMP - it activates AMPK both allosterically and by inhibiting dephosphorylation of AMPK. Shown to inhibit Na+-K+-ATPase at higher concentrations (IC₅₀ = 57 μM) . Inhibits differentiation of adipocytes.
The product is subject to the following: Abcam Restricted Use Statement